BLUE bluebird bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BLUE

Price (delayed)

$2.9

Market cap

$310.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.88

Enterprise value

$444.15M

bluebird bio, Inc., based in Cambridge, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders and cancer. The company's only - in the European Union - ...

Highlights
The revenue has surged by 133% since the previous quarter and by 54% year-on-year
The EPS has surged by 89% year-on-year and by 44% since the previous quarter
The quick ratio has soared by 101% YoY but it has contracted by 33% from the previous quarter
The gross margin has soared by 91% YoY but it has contracted by 37% from the previous quarter
bluebird bio's debt has increased by 12% from the previous quarter and by 4.7% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: BMRN SGMO GLYC MRK

Key stats

What are the main financial stats of BLUE
Market
Shares outstanding
106.95M
Market cap
$310.16M
Enterprise value
$444.15M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.07
Price to sales (P/S)
33.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
47.22
Earnings
Revenue
$9.41M
EBIT
-$102.18M
EBITDA
-$97.48M
Free cash flow
-$100.04M
Per share
EPS
-$0.88
Free cash flow per share
-$0.92
Book value per share
$2.72
Revenue per share
$0.09
TBVPS
$6
Balance sheet
Total assets
$663.39M
Total liabilities
$374.37M
Debt
$306.86M
Equity
$289.02M
Working capital
$152.96M
Liquidity
Debt to equity
1.06
Current ratio
2.13
Quick ratio
1.93
Net debt/EBITDA
-1.37
Margins
EBITDA margin
-1,036.5%
Gross margin
-37.8%
Net margin
-1,020.3%
Operating margin
-1,448.2%
Efficiency
Return on assets
-15.8%
Return on equity
-38.4%
Return on invested capital
-16.8%
Return on capital employed
-19.3%
Return on sales
-1,086.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BLUE stock price

How has the bluebird bio stock price performed over time
Intraday
-4.61%
1 week
-4.29%
1 month
-25.64%
1 year
-54.19%
YTD
-58.09%
QTD
-4.61%

Financial performance

How have bluebird bio's revenue and profit performed over time
Revenue
$9.41M
Gross profit
-$3.56M
Operating income
-$136.21M
Net income
-$95.96M
Gross margin
-37.8%
Net margin
-1,020.3%
The revenue has surged by 133% since the previous quarter and by 54% year-on-year
The gross margin has soared by 91% YoY but it has contracted by 37% from the previous quarter
bluebird bio's net margin has soared by 90% YoY and by 67% from the previous quarter
The gross profit has soared by 87% YoY

Growth

What is bluebird bio's growth rate over time

Valuation

What is bluebird bio stock price valuation
P/E
N/A
P/B
1.07
P/S
33.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
47.22
The EPS has surged by 89% year-on-year and by 44% since the previous quarter
bluebird bio's equity has soared by 60% YoY but it has decreased by 19% from the previous quarter
BLUE's P/B is 53% below its 5-year quarterly average of 2.4 and 44% below its last 4 quarters average of 2.0
The revenue has surged by 133% since the previous quarter and by 54% year-on-year
BLUE's P/S is 62% below its last 4 quarters average of 92.7

Efficiency

How efficient is bluebird bio business performance
The return on sales has surged by 89% year-on-year and by 65% since the previous quarter
bluebird bio's return on invested capital has surged by 85% YoY and by 20% QoQ
bluebird bio's ROA has soared by 80% YoY and by 25% from the previous quarter
bluebird bio's ROE has soared by 73% YoY and by 31% from the previous quarter

Dividends

What is BLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLUE.

Financial health

How did bluebird bio financials performed over time
The total assets is 77% greater than the total liabilities
The quick ratio has soared by 101% YoY but it has contracted by 33% from the previous quarter
The current ratio has soared by 90% YoY but it has contracted by 30% from the previous quarter
bluebird bio's debt is 6% more than its equity
bluebird bio's equity has soared by 60% YoY but it has decreased by 19% from the previous quarter
BLUE's debt to equity is up by 38% since the previous quarter but it is down by 35% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.